SKF-96365 是一种 TRPC 通道拮抗剂和钙库操纵性钙内流 (SOCE) 抑制剂,可抑制 TRPC6、STIM1 和 Orai1 的活性与表达以减少钙离子内流,抑制电压门控钠电流 (心肌 INa/NaV1.5) 并减慢心肌传导,抑制 CaMKIIγ 的磷酸化/激活及下游 AKT 信号通路,诱导结直肠癌细胞发生 G2/M 期细胞周期阻滞、凋亡 (apoptosis) 和细胞保护性自噬 (autophagy),降低炎性细胞因子水平以缓解变应性鼻炎症状,减轻细胞内钙超载、抑制 Homer1 表达、阻止细胞核损伤并抑制细胞凋亡 (apoptosis),同时抑制裸鼠体内结直肠癌异种移植物的生长,可用于变应性鼻炎、结直肠癌、帕金森病、持续性自发性伤害感受及痛觉过敏的相关研究。
产品编号: MS-B34454 纯度: 99.97% CAS No.: 162849-90-3 分子式: C22H26N2O3 分子量: 366.45
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价

产品描述

SKF-96365 是一种 TRPC 通道拮抗剂和钙库操纵性钙内流 (SOCE) 抑制剂,可抑制 TRPC6、STIM1 和 Orai1 的活性与表达以减少钙离子内流,抑制电压门控钠电流 (心肌 INa/NaV1.5) 并减慢心肌传导,抑制 CaMKIIγ 的磷酸化/激活及下游 AKT 信号通路,诱导结直肠癌细胞发生 G2/M 期细胞周期阻滞、凋亡 (apoptosis) 和细胞保护性自噬 (autophagy),降低炎性细胞因子水平以缓解变应性鼻炎症状,减轻细胞内钙超载、抑制 Homer1 表达、阻止细胞核损伤并抑制细胞凋亡 (apoptosis),同时抑制裸鼠体内结直肠癌异种移植物的生长,可用于变应性鼻炎、结直肠癌、帕金森病、持续性自发性伤害感受及痛觉过敏的相关研究。

生物实验数据

生物活性 SKF-96365 is a TRPC channel antagonist and store-operated calcium entry (SOCE) inhibitor that inhibits the activity and expression of TRPC6, STIM1, and Orai1 to reduce calcium influx, inhibits voltage-gated sodium currents (cardiac INa/NaV1.5) and slows cardiac conduction, inhibits CaMKIIγ phosphorylation/activation and the downstream AKT signaling pathway, induces G2/M cell cycle arrest, apoptosis, and cytoprotective autophagy in colorectal cancer cells, reduces inflammatory cytokine levels to alleviate allergic rhinitis symptoms, attenuates intracellular calcium overload, inhibits Homer1 expression, prevents nuclear damage, and suppresses apoptosis, and inhibits the growth of colorectal cancer xenografts in nude mice, making it applicable for research on allergic rhinitis, colorectal cancer, Parkinson's disease, persistent spontaneous nociception, and hyperalgesia.
体外研究
(In Vitro)

SKF-96365 (0-10 μM; until steady-state inhibition reached) 抑制表达于 HEK 293 细胞中的 hNaV1.5 电流,IC50 为 0.94 μM。
SKF-96365 (0-20 μM) 可剂量依赖性地抑制 HCT116 和 HT29 人结直肠癌细胞中的钙库操纵性钙内流。
SKF-96365 (0-40 μM,48-72 h) 抑制人结直肠癌细胞 HCT116 (IC50 = 10.88 μM) 和 HT29 (IC50 = 14.56 μM) 的生长,且对正常结肠上皮细胞 NCM460 的毒性显著更低。
SKF-96365 (0-20 μM,48 h) 通过调控关键的 G2/M 期转换蛋白 (包括上调 p21waf/Cip1、下调 p-Cdc25c、Cdc25c 和 Cyclin B),在人结直肠癌细胞 HCT116 和 HT29 中诱导 G2/M 期细胞周期阻滞。
SKF-96365 (10 μM,0-24 h) 可通过内源性线粒体通路诱导人结直肠癌细胞 HCT116 和 HT29 发生凋亡,其过程表现为早期 (12 h) 线粒体膜去极化、Bax 转位及细胞色素 c 释放,随后出现半胱天冬酶激活和显著凋亡 (24 h)。
SKF-96365 (0-20 μM,12 h) 可在人结直肠癌细胞 HCT116 和 HT29 中诱导具有细胞保护作用的自噬,该作用最早可在 12 h 出现 (早于细胞凋亡),并通过将线粒体隔离至自噬泡中以降低胞质细胞色素 c 水平,从而拮抗细胞凋亡。
SKF-96365 (0-20 μM,24 h) 可抑制人结直肠癌细胞 HCT116 和 HT29 中的 AKT/mTOR 信号通路,抑制人结直肠癌细胞 HCT116 和 HT29 中的钙/Ca2+/CaMKIIγ/AKT 信号通路。
SKF-96365 (1-50 μM,24 h) 可显著提高经 MPP+处理的 PC12 细胞的存活率,降低细胞的 LDH 释放量,降低细胞的细胞核损伤、膜损伤、晚期凋亡性细胞死亡、减轻 细胞内钙超载、降低 Homer1 的 mRNA 和蛋白表达水平。
SKF-96365 (1-10 µM) 呈剂量依赖性抑制急性分离的大鼠中小型背根神经节细胞中蜂毒肽诱导的内向电流。
SKF-96365 (10 µM) 可抑制蜂毒肽诱导的细胞内 Ca2+ 升高,在对蜂毒肽敏感的急性分离大鼠背根神经节细胞中,该抑制作用的细胞占比为 46.5%。

Cell Viability Assay

Cell Line: PC12 (adrenal gland pheochromocytoma) cells
Concentration: 1 μM, 10 μM, 50 μM
Incubation Time: 30 min pretreatment before MPP+ insult; 24 h post-MPP+ measurement
Result: Significantly inhibited the MPP+-induced decrease in cell viability at 10 μM and 50 μM, with viability levels significantly higher than the MPP+-treated vehicle group.
Did not show a significant effect on cell viability compared to the vehicle group at 1 μM.
Did not affect cell viability in untreated normal PC12 cells at all tested concentrations.

Apoptosis Analysis

Cell Line: PC12 cells
Concentration: 50 μM
Incubation Time: 30 min pretreatment before MPP+ insult; 24 h post-MPP+ flow cytometry
Result: Increased the percentage of normal (AV-/PI-) cells compared to the MPP+-treated vehicle group.
Decreased the percentage of late apoptotic (AV+/PI+) cells compared to the MPP+-treated vehicle group.
Showed no significant effect on necrotic (AV-/PI+) cells.

Real Time qPCR

Cell Line: PC12 cells
Concentration: 50 μM
Incubation Time: 30 min pretreatment before MPP+ insult; measured at 3 h, 6 h, 12 h post-MPP+
Result: Significantly decreased Homer1 mRNA expression in a time-dependent manner, with significant reductions observed at 3 h, 6 h, and 12 h post-MPP+ insult compared to the MPP+-treated vehicle group.
MPP+ alone did not alter Homer1 mRNA expression compared to untreated control cells.

Western Blot Analysis

Cell Line: PC12 cells
Concentration: 50 μM
Incubation Time: 30 min pretreatment before MPP+ insult; measured at 3 h, 6 h, 12 h post-MPP+
Result: Significantly decreased Homer1 protein expression in a time-dependent manner, with significant reductions observed at 3 h, 6 h, and 12 h post-MPP+ insult compared to the MPP+-treated vehicle group.
MPP+ alone did not alter Homer1 protein expression compared to untreated control cells.
体内研究
(In Vivo)

SKF-96365 (200-400 μg;鼻腔给药;每日 1 次;连续 8 天) 缓解 BALB/c 小鼠的过敏性鼻炎症状并抑制炎症反应。
SKF-96365 (20 mg/kg;腹腔注射;每日 1 次;连续 14 天) 可通过抑制 CaMKIIγ/AKT 介导的通路,诱导细胞周期阻滞、细胞凋亡及保护性自噬,从而抑制无胸腺 BALB/c 裸鼠体内结直肠癌异种移植物的生长。

Animal Model: athymic BALB/c nude (5-6-week-old female; subcutaneous xenograft model via HCT116 cell inoculation)
Dosage: 20 mg/kg
Administration: i.p.; daily; 14 days
Result: Reduced tumor growth compared to vehicle control.
Decreased tumor tissue expression of phosphorylated AKT (p-AKT) and proliferating cell nuclear antigen (PCNA).
Increased expression of cleaved caspase-3 and LC3-II.
Decreased levels of phosphorylated CaMKII (p-CaMKII) and p-AKT in tumor lysates via western blot analysis.
Increased levels of LC3-II, cleaved PARP, cleaved caspase-3, and cleaved caspase-9 in tumor lysates via western blot analysis.
Caused no significant weight loss or liver/kidney injury.
Animal Model: BALB/c (female; allergic rhinitis model via intraperitoneal sensitization and intranasal challenge)
Dosage: 200 μg; 400 μg
Administration: i.n.; once daily; 8 days (1 hour before ovalbumin challenge)
Result: Significantly reduced frequencies of sneezing and nasal rubbing compared to untreated allergic rhinitis mice, with the 400 μg dose being more effective than the 200 μg dose.
Significantly decreased serum levels of OVA-specific IgE, histamine, and LTC4 compared to untreated allergic rhinitis mice, with greater reductions observed in the 400 μg group.
Significantly decreased nasal lavage fluid levels of OVA-specific IgE, IL-4, IL-5, IL-6, IL-13, and IL-33 compared to untreated allergic rhinitis mice, with greater reductions observed in the 400 μg group.
Significantly decreased counts of total inflammatory cells, eosinophils, macrophages, neutrophils, and lymphocytes in nasal lavage fluid compared to untreated allergic rhinitis mice, with greater reductions observed in the 400 μg group.
Reduced eosinophil counts in nasal mucosa compared to untreated allergic rhinitis mice, with the 400 μg dose producing more pronounced effects than the 200 μg dose.
Downregulated TRPC6 immunolabeling in nasal mucosa compared to untreated allergic rhinitis mice, with the 400 μg dose producing more pronounced effects than the 200 μg dose.
Decreased nasal mucosa mRNA levels of TRPC6, STIM1, and Orai1 compared to untreated allergic rhinitis mice, with the 400 μg dose producing more pronounced effects than the 200 μg dose.
性状 油状物
颜色 Colorless to light yellow

化学信息

分子量 366.45
分子式 C22H26N2O3
CAS No. 162849-90-3

储存&溶解度

储存方式
Pure form -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (272.89 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.7289 mL13.6444 mL27.2889 mL68.2221 mL
5 mM0.5458 mL2.7289 mL5.4578 mL13.6444 mL
10 mM0.2729 mL1.3644 mL2.7289 mL6.8222 mL
15 mM0.1819 mL0.9096 mL1.8193 mL4.5481 mL
20 mM0.1364 mL0.6822 mL1.3644 mL3.4111 mL
25 mM0.1092 mL0.5458 mL1.0916 mL2.7289 mL
30 mM0.0910 mL0.4548 mL0.9096 mL2.2741 mL
40 mM0.0682 mL0.3411 mL0.6822 mL1.7056 mL
50 mM0.0546 mL0.2729 mL0.5458 mL1.3644 mL
60 mM0.0455 mL0.2274 mL0.4548 mL1.1370 mL
80 mM0.0341 mL0.1706 mL0.3411 mL0.8528 mL
100 mM0.0273 mL0.1364 mL0.2729 mL0.6822 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础